Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection : A Longitudinal Study
Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection.
Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19).
Study Design: A longitudinal study.
Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value.
Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19.
Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Balkan medical journal - 39(2022), 3 vom: 24. Mai, Seite 172-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dinç, Harika Öykü [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 26.05.2022 Date Revised 16.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4274/balkanmedj.galenos.2022.2021-8-131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339084235 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339084235 | ||
| 003 | DE-627 | ||
| 005 | 20231226002121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4274/balkanmedj.galenos.2022.2021-8-131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339084235 | ||
| 035 | |a (NLM)35378574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dinç, Harika Öykü |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection |b A Longitudinal Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2022 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection | ||
| 520 | |a Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19) | ||
| 520 | |a Study Design: A longitudinal study | ||
| 520 | |a Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value | ||
| 520 | |a Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19 | ||
| 520 | |a Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Demirci, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Özdemir, Yusuf Emre |e verfasserin |4 aut | |
| 700 | 1 | |a Sirekbasan, Serhat |e verfasserin |4 aut | |
| 700 | 1 | |a Aktaş, Ayse Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Karaali, Rıdvan |e verfasserin |4 aut | |
| 700 | 1 | |a Tuyji Tok, Yeşim |e verfasserin |4 aut | |
| 700 | 1 | |a Özbey, Doğukan |e verfasserin |4 aut | |
| 700 | 1 | |a Akçin, Rüveyda |e verfasserin |4 aut | |
| 700 | 1 | |a Gareayaghi, Nesrin |e verfasserin |4 aut | |
| 700 | 1 | |a Kuşkucu, Mert Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Midilli, Kenan |e verfasserin |4 aut | |
| 700 | 1 | |a Aygün, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Sarıbaş, Suat |e verfasserin |4 aut | |
| 700 | 1 | |a Kocazeybek, Bekir |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Balkan medical journal |d 2012 |g 39(2022), 3 vom: 24. Mai, Seite 172-177 |w (DE-627)NLM241766915 |x 2146-3131 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:3 |g day:24 |g month:05 |g pages:172-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4274/balkanmedj.galenos.2022.2021-8-131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 3 |b 24 |c 05 |h 172-177 | ||